Keefe, S. M., Hoffman-Censits, J. H., Mamtani, R., Walicki, M., Robinson, J., Smith, A., … Haas, N. B. (2015). HIF inhibition in metastatic renal cell carcinoma (mRCC): Final results of a phase Ib /IIa clinical trial evaluating the nanoparticle drug conjugate (NDC), CRLX101, in combination with bevacizumab (bev). In Journal of Clinical Oncology (Vol. 33, pp. 4543–4543). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2015.33.15_suppl.4543

Keefe, Stephen Michael, Jean H. Hoffman-Censits, Ronac Mamtani, Mary Walicki, Janelle Robinson, Abigail Smith, Orvar Gunnarsson, et al. “HIF inhibition in metastatic renal cell carcinoma (mRCC): Final results of a phase Ib /IIa clinical trial evaluating the nanoparticle drug conjugate (NDC), CRLX101, in combination with bevacizumab (bev).” In Journal of Clinical Oncology, 33:4543–4543. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.4543.

Keefe SM, Hoffman-Censits JH, Mamtani R, Walicki M, Robinson J, Smith A, et al. HIF inhibition in metastatic renal cell carcinoma (mRCC): Final results of a phase Ib /IIa clinical trial evaluating the nanoparticle drug conjugate (NDC), CRLX101, in combination with bevacizumab (bev). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. 4543–4543.

Keefe, Stephen Michael, et al. “HIF inhibition in metastatic renal cell carcinoma (mRCC): Final results of a phase Ib /IIa clinical trial evaluating the nanoparticle drug conjugate (NDC), CRLX101, in combination with bevacizumab (bev).” Journal of Clinical Oncology, vol. 33, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2015, pp. 4543–4543. Crossref, doi:10.1200/jco.2015.33.15_suppl.4543.

Keefe SM, Hoffman-Censits JH, Mamtani R, Walicki M, Robinson J, Smith A, Gunnarsson O, Piscitelli A, Hennessey M, Jayaraman L, Nixon AB, Eliasof S, Cohen RB, Vaughn DJ, Garmey EG, Haas NB. HIF inhibition in metastatic renal cell carcinoma (mRCC): Final results of a phase Ib /IIa clinical trial evaluating the nanoparticle drug conjugate (NDC), CRLX101, in combination with bevacizumab (bev). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. 4543–4543.